An analysis of reported cases shoulder injury related to vaccine administration of after COVID-19 vaccination.

Publication date: Dec 31, 2024

To prevent COVID-19, the COVID-19 vaccine has been widely administered worldwide, but various complications accompany this vaccine. The aim of this study was to investigate the demographic patterns, clinical features, diagnostic findings, and treatment outcomes associated with shoulder injury related to vaccine administration (SIRVA). This study examined 22 patients with SIRVA following COVID-19 vaccination from the Web of Science (WOS) and PubMed databases. The patients were categorized based on sex, age, type of COVID-19 vaccine received, dose administered, latency of symptom onset, and the presence of specific clinical manifestations. Patients, evenly distributed by sex (12 females, 10 males), and aged 21 to 84 years (mean age 46. 6), were analyzed. SIRVA cases were reported across all age groups. The Pfizer – BioNTech COVID-19 vaccine had the highest incidence (n = 8), followed by the Oxford/AstraZeneca COVID-19 vaccine (n = 4). Symptoms, primarily shoulder pain (n = 22) and shoulder mobility disorders (n = 18), occurred within three days post-vaccination. Some patients also reported shoulder swelling (n = 5) and fever (n = 2). Imaging revealed nonspecific X-ray findings, supraspinatus tendon calcification (n = 2), and shoulder edema and inflammation on MRI (n = 12). This study provides insights into the clinical aspects of SIRVA related to COVID-19 vaccination. Recognition and appropriate management of these complications are crucial for optimal patient outcomes.

Concepts Keywords
84years clinical characteristics
Astrazeneca COVID-19 vaccine
Females shoulder injury
Vaccine treatment outcomes


Type Source Name
disease VO vaccine
disease MESH COVID-19
disease VO vaccination
disease VO COVID-19 vaccine
disease MESH complications
disease VO dose
disease IDO symptom
disease MESH edema
disease MESH inflammation

Original Article

(Visited 1 times, 1 visits today)